Biogen Issues Q4 2019 Community Statement on Spinraza
Dear Members of the SMA Community, As part of Biogen’s ongoing commitment to individuals living with, and caregivers affected by, spinal muscular atrophy (SMA), we are pleased to announce updates to our SPINRAZA® (nusinersen) clinical development program – an extensive clinical data set in the treatment of SMA to date that includes more than 300 […]
Biogen Issues Q4 2019 Community Statement on Spinraza Read More »

